Navigation Links
Genetic Engineering & Biotechnology News reports on cancer biomarkers
Date:4/1/2008

New Rochelle, NY, April 1, 2008Biotechnology companies are focusing on the development of novel biomarkers to overcome the limitations of current diagnostic tests for cancer, reports Genetic Engineering and Biotechnology News (GEN). To effectively move cancer therapy forward, a much stronger and targeted emphasis on diagnosis will be required, according to an article in the April 1 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2428).

"Therapeutic protocols can involve hundreds of thousands of dollars per cancer patient," notes John Sterling, Editor-in-Chief of GEN (www.genengnews). "Coming up with effective and validated biomarkers that detect cancer while still in its early stages seems like an extremely worthwhile effort on which to spend R&D funds now to cut down on costs of treatment in the future."

A team led by Edouard Nice, Ph.D., at the Ludwig Institute for Cancer Research, is one example of a group hard at work trying to develop early detection tools for malignancies. Dr. Nice and his colleagues are using multidimensional high-performance liquid chromatography to trace enrich low-level components such as growth factors in tumor material prior to analysis by mass spectrometry.

At Wayne State University School of Medicine, a research program run by Michael Tainsky, Ph.D., harnesses antibodies in patients' serum for the detection of cancer-specific epitopes using peptides selected for IgG binding from phage-display cDNA libraries.

Other biomarker-related projects covered in the GEN article include those at Sienna Cancer Diagnostics, Geron, Quest Diagnostics Nichols Institute, Gentel Biosciences, Celera, University of Washington, Abbott Laboratories, Strategic Diagnostics, Plasma Proteome Institute, and Biosite.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
3. Many parents at-risk for cancer disclose genetic test results to children
4. Genetics determine optimal drug dose of common anticoagulant
5. Claims of sex-related differences in genetic association studies often not properly validated
6. American College of Medical Genetics responds to new FDA labeling decision for warfarin
7. UNC study questions FDA genetic-screening guidelines for cancer drug
8. Genome study shines light on genetic link to height
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
11. Rutgers Genetics receives $7.8 million for autism research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... NEW YORK , June 22, 2016 /PRNewswire/ ... the growing next generation sequencing (NGS) market include ... adoption of smaller sequencers.  More accessible and affordable ... led to growing demand for consumables including sample ... The Market for Sample Preparation for Next ...
(Date:6/22/2016)... , June 22, 2016   ViaCyte, Inc. , ... stem cell-derived islet replacement therapy for the treatment of ... ISSCR 2016 Annual Meeting.  ISSCR 2016, the Global Stem ... at Moscone West in San Francisco.  ... presentations are as follows:Event: , Focus Session: Tools for ...
(Date:6/22/2016)... 2016  Mesa Biotech Inc., a privately-held, molecular ... designed specifically for point-of-care (POC) infectious disease diagnosis, ... board (SAB). Approved by the executive leadership team ... to advise on the development and commercialization of ... Dr. Steve Young , this world-class team ...
(Date:6/21/2016)... NANJING , China , June ... that a Phase 2 clinical trial for its novel ... statistically significant (p=0.023) and clinically meaningful pain relief against ... the United States , the trial enrolled 146 ... statistically significant (1) analgesia against placebo at week-1 (p=0.024), ...
Breaking Biology Technology: